Introduction
Liver transplantation (LT) is currently the treatment of choice for patients with advanced chronic liver failure for which no other therapy is available. Despite great technological and immunological advances in the field of LT, there are still significant complications of recipients [1] . These complications include biliary, vascular, neurological, SFSS, early rejection, pneumonia, gastrointestinal hemorrhage, renal insufficiency or failure, bowel obstruction, postoperative collections, infection and malignant recurrence [2e7] . The previous complications have a significant impact on the morbidity and mortality of recipients [8] . Examples of mortality causes are infections, disease recurrence, malignancy, cardiovascular event, and renal failure [9] . So, these potential complications need to be minimized to improve immediate and long-term outcomes after LDLT [10] . The purpose of this work was to analyze complications and mortality of patients after (A-ALDLT) in a single center.
Patients and methods
After approval of institutional review board (IRB), we did this retrospective cohort study that analyzed complications and mortality in recipients in the department of hepatopancreatobiliary (HPB) surgery, national liver institute (NLI), university of Menoufiya, Menoufiya, Egypt, in the period from April 2003 to November 2013 with median follow up period of 24.7 ± 25.9 m (range, 0e120 m). The study included 167 (AeA LDLT) patients who had operations between April 2003 and February 2013. The data were collected from our records in the liver transplantation unit of our institute and written informed consents were obtained from both donors and recipients regarding operations and researches. We excluded patients with missing data and who did not complete the follow-up.
I Patients
The characteristics of recipients and donors (including operative parameters) and the indication for liver transplantation are shown in Tables 1 and 2. A Characteristics of patients and their donors (including operative parameters)
They were classified as 147 (88%) males, and 20 (12%) females. Their mean age was 46.3 ± 8.2. Their donors were classified as 114 (68.3%) males and 53 (31.7%) females, their mean age was 26.9 ± 6.5. The patients were classified according to Child-Pugh score into 9 (5.4%) class A, 50 (29.9%) class B, and 108 (64.7%) class C, and mean model for end stage liver disease (MELD) score was 16.1 ± 4.2. Sixty one (36.5%) of them had co morbidities, in the form of Hypertension, DM, cardiac diseases and morbid obesity. Portal HTN affected 160 (95.8%) of them. The donor to recipient Bl. Group matching was classified into identical in 119 (71.3%) and Compatible in 48 (28.7%) of them. The right lobe graft was given to 159 (95.2%) and the left lobe was given to 8 (4.8%) of them. The mean actual graft weight and actual graft recipient weight ratio (GRWR) were 819.4 ± 172.1 gm and 1.04 ± 0.20 gm respectively. While the mean cold and warm ischemia times were 74.9 ± 52.1 min and 52.1 ± 16.05 min respectively. The mean intraoperative blood transfusion was 7 ± 7.4 units Table 1 .
B Indications of LT
The most frequent indications were HCV followed by HCC Table 2 . 
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II Methods
All donors were <19 years old and the donor work-up included liver function tests, liver biopsy, ultrasound examination, psychological assessment and CT angiography, along with hepatic volumetric study and vascular reconstructions [11] .
A The donor and recipient operations 1 In the donor operation, the right or left lobes of the liver were mobilized and the vena cava was dissected. The CUSA device was used to divide the liver parenchyma without inflow occlusion. The falciform ligament was reconstructed, the stumps of the divided hepatic and portal veins were closed by continuous nonabsorbable sutures, after graft harvesting, it was perfused in the back-table with hydroxy tryptophan ketoglutarate (HTK) solution and weighted to determine the actual GRWR (graft weight per gram Â 100/patient weight per KGx1000), if it was less than 0.8, the graft was named small for size graft (SFSG) [12] . 2 In the recipient surgery, the native liver was explanted while carefully preserving the inferior vena cava. After reconstructing the hepatic and portal veins, the hepatic artery was anastomosed by the use of a surgical loupe or microscopy. The biliary tract was reconstructed by a duct-to-duct hepatico-choledochostomy or a Roux-en-Y hepatico-jejunostomy [13] . B post-operative management 1 Patients were given prophylactic therapy (Based on our institutional policy) in the form of: . The initial methylprednisolone dose was 500 mg intra-operatively with a brief taper of prednisone from 240 to 40 mg/d over 6 days followed by 5e20 mg/d maintenance treatment, with complete withdrawal at the end of 3rd month post LDLT. Cyclosporine (CsA) was used when neurotoxicty or nephrotoxicity developed with Tacrolimus. When CNIs were contraindicated or their side effects halted their use, sirolimus (SRL) was given at an initial dose of 3 mg/m 2 and adjusted over time to achieve blood trough levels of approximately 5e8 ng/ mL. The post-operative anti-HBV protocols consisted of lamivudine combined with therapy with a low-dose of intramuscular hepatitis B immune globulin. Hepatitis B immune globulin was administered to all recipients with HBV infection during and after the transplantation [12,14e16] . 3 post-operative follow-up until the end of follow-up period (The follow-up of post transplant patients was conducted by a team with transplant surgeon and transplant hepatologist) to detect: a Complications (Biliary, vascular, small for size syndrome and etc … …..). Clavien's modified 5-tier scoring system [25] was used for grading recipient complications Table 3 in preference to his original version [26] which had only four grades [26] . b Mortality of patients: i-In hospital mortality (during the 1st hospital admission). ii-Late mortality (after discharge till the end of the follow-up period).
Statistical techniques
All data were tabulated and processed with SPSS software (statistical Product and Service solutions, version 21, SSPS Inc, Chicago, IL, USA) and Windows XP (Microsoft Corporation, Redmond, Washington, USA).
Qualitative data were expressed in frequency and percentage and analyzed with the chi-square or Fisher exact tests. Quantitative data were expressed as the mean and standard deviation or median and range and were compared with the t or Mann whitteny test. The previous (preoperative, intra-operative and post-operative) variables were descriptively studied. Univariate analysis and then multivariate analysis for significant predictors in univariate analysis were done to detect the relationship between complications and mortality of patients in the follow up period after A-ALDLT. The KaplaneMeier method was applied for survival analysis and compared using log-rank tests. In all tests, a P value of <0.05 was considered significant.
Results
One hundred forty four (86.2%) of our patients had one or more than one complication graded from two to five regarding Clavien's modified 5-tier scoring system (26) where biliary complications were the most frequent 73/167 (43.7%) in the form of biliary leak, biliary stricture or leak with stricture, and according to Clavien grading, grades II, III, IV and V involved 8, 52, 1 and 12 of them respectively (Table 4) . These biliary complications were managed as follow:1-for biliary leak the 1st treatment option was insertion of pigtail for drainage or conservative treatment but if failed; endoscopic retrograde cholangio pancreatography (ERCP) with stent or surgical repair were done. 2-for biliary stricture, the 1st treatment option was ERCP with stent but if failed surgical repair was done. Figs. 1 and 2.
The incidence of vascular complications was 36/167 (21.6%) that was classified into HA problems (HA stenosis, HAT( a case associated with HA aneurysm) or HA injury), PV problems (PV stenosis or PVT), HV problems (HV stenosis or HVT) and IVC injury. As regard Clavien grading, grades II, III, IV and V involved 6, 18, 2 and 10 of them respectively (Table 4 ). The management of vascular complications included: medical (anticoagulants or thrombolytic therapy), angiography (dilatation, stenting, coling of GDA or thrombolytic therapy) or surgery (thrombectomy or reanastomosis) Figs. 3 and 4. SFSS (characterized clinically by a combination of prolonged functional cholestasis, intractable ascites, and delayed functional recovery of both prothrombin time and encephalopathy) affected 21/167 (12.6%) of our patients and for prevention of this syndrome we performed splenectomy in some cases with SFSG and performed multiple HV anastomoseses (MHV, RT inferior V, segment 5 or segment 8 v) to improve venous drainage. Furthermore, Grades II and V involved 11 and 10 of them respectively. (Table 4) .
Recurrent HCV affected 16.8% of our patients and treated with PEG-IFN-a-2b (PEG-Intron, Schering Plough, Kenilworth, NJ, USA) which was administered subcutaneously at a weekly dose of 1 mg/ kg of body weight plus Ribavirin (Rebetol, Schering Plough, Kenilworth, NJ, USA) that was administered orally at the starting daily dose of 400e800 mg/day. Planned duration of treatment was 48 weeks. Patients who were HCV RNA-positive after 12 weeks of treatment were considered as non-responders and treatment was stopped. On the other hand 4 patients had recurrent HCC and managed with surgery followed by nexavar (3 patients) or radiotherapy for bone recurrence (1 patient). Table 4 Acute rejection affected 32 patients and was treated with steroid pulses (IV methylprednisolone 200e500 mg/d for 3 days), which were tapered over several days to the baseline dose Table 4 .
Bacterial infection affected 21.6% of patients and was treated by antibiotics according to culture and sensitivity Table 4 . In our work, biloma affected 12 patients and was managed conservatively or by pigtail drainage. However three patients suffered multiple hepatic abscesses and were managed with antibiotics, multiple pigtail drainage and treating the predisposing vascular cause (I.e. HAT). Table 5 .
Lastly, neurological and renal complications were managed with neurological and renal supportive treatment respectively Table 5 .
Outcome of patients
The overall mortality was 75 (44.9%). The incidence of in hospital mortality was 28.7% and its most frequent cause was SFSS (6%), while the incidence of late mortality was 16.2% and its most frequent cause was sepsis (7.2%). On the other hand, the overall 6-months, 1-, 3-5-and 7-year survival of our patients were Table 6 .
5 Complications as predictors of outcome A On univariate analysis, the following complications were found to be statistically significant predictors of poor outcome: Vascular, wound, intra abdominal collection and SFSS complications. On the other hand, there were trends towards significant poor outcome with the following complications: biliary, chest, neurological and acute rejection complications Table 7 . Fig. 6 . B On multivariate analysis by Cox regression analysis, vascular complications and SFSS were independent predictors of poor outcome. Table 8 .
Discussion
LDLT can now be performed with a reasonably high rate of success attributable to judicious patient selection, careful preoperative evaluation, excellent anesthetic management and aggressive care to promptly detect and treat complications [27] . A-ALDLT has a high surgical risk and complications for the recipient because of the differences in graft quality, size, and preservation time [5] . In our study, the mortality was higher among our complicated cases but without statistical significance. On the other hand, it was significantly higher in patients with complications in Ho et al., 2004 [28] .
The overall post-operative complication rate in our study was 86.2%, and this high rate occurred due to including all types of complications (single, multiple, minor, major, complications treated medically, by intervention endoscopy, radiology and that treated surgically), Similarly it was 60%, 78.13%, 66%, and 58. [5] study because they did not include the long term complications.
The overall incidence of biliary complications in LDLT patients ranges from 15 to 60% [29, 30, 32, 33] . On the other hand, it was 43.7% in our study and 33.6%, 31% and 25% in Shin et al., 2013 [4] , Goldstein et al., 2003 [14] and V€ ali et al., 2010 [31] studies respectively. These biliary complications remain a major cause of morbidity and mortality after LT [6,34e36] . Similarly there was a trend towards significant mortality among our biliary complicated cases.
Vascular problems such as thrombosis and stenosis of the hepatic artery, portal vein, and hepatic vein are among the most serious complications reported after LT and are more frequently seen among recipients of LDLT. The prevalence of vascular complications after LT ranges from 7% to 25% [37] . However it was 21.6% in the present study and 13.1%, 21%, 12.1%, 15%, 16.6%, 7%, and 13% of the LDLT group in Shin [38] and Khalaf, 2010 [39] studies respectively. On the other hand, it was higher (48.5%) In Abdelaziz et al., 2013 [7] study and lower 5.6% in Du et al., 2 0 1 3 [5] study. These vascular complications were independent predictor of mortality in our study, similarly it was associated with poor [38] and Khalaf, 2010 [39] studies. The use of SFSG leads to SFSS, including poor bile production, delayed synthetic function, prolonged cholestasis and intractable ascites, with subsequent septic complications and higher mortality [40e42] . Similarly, SFSS was independent predictor of high mortality in our study, In contrast, it did not affect mortality in Kiuchi et al., 2010 [43] study. The incidence of this syndrome in our study was 12.6%, however it was 15.7% and 22% in Du et al., 2013 [5] and Goldstein et al., 2003 [14] studies respectively.
The incidence of renal impairment (RI) was 21% in our study, however it was 6.2%,19.2%, 62.7%, and 29% in Du et al., 2 0 1 3 [5] , Lin et al., 2004 [27] , Kuramitsu et al., 2014 [44] , and Akamatsu et al., 2006 [45] studies respectively, in our study RI did not affect survival, similarly, it did not affect survival, in Akamatsu et al., 2006 [45] study. In contrast, it lead to mortality in Iwata et al., 2014 [46] study.
Acute rejection is a common cause of graft failure, clinical, laboratory and radiological findings are non-specific and the definite diagnosis is achieved only after liver biopsy [47] . In our study, the incidence of acute rejection was 19.2%, however it was 14.4%,10.6%, 6%, 13%, and 15. [27] and studies respectively. The higher incidence of acute rejection in our study occurred due to adjusting the immunosuppressant dose to their lower limit for fear of neurotoxicity and nephrotoxicity and to avoid the occurrence of sepsis that was the 2nd cause of early mortality in our work.
Recurrence of hepatocellular carcinoma (HCC) after LT is considered to result from undetected extrahepatic metastasis before surgery or the release of tumor cells during surgical manipulation [48] . The most common site of recurrence is the lung and the second most common site is the liver [49] . In Abdelaziz et al., 2013 [7] study, 60% developed hepatic recurrent HCC and 23% suffered from intrahepatic and extrahepatic HCC recurrence at 1-y after transplantation. In (Du et al., 2 0 1 3 [5] study. On the other hand, only 7% had recurrent HCC in our study. The reason for this low incidence was that a large number of our HCC cases had inhospital mortality so there was no enough time to detect HCC recurrence.
The incidence of hepatitis C recurrence was 56.4%, 33.3%, and 26.3% in Shin et al., 2013 [4] , Du et al., 2 0 1 3 [5] , and Yosry et al., 2008 [50] studies respectively and 19.2% in our study. This low incidence was due to putting strict criteria for detecting HCV recurrence, these are the biochemical, serological and histological evidences of recurrence, so we did not mention that HCV recurrence occurred until the patient fulfill all the previous parameters.
The incidence of neurological problems after LT ranges from 10 to 47% [2, 51] . On the other hand, it reached 26.3% in our study. The spectrum of the clinical presentations is extremely wide, ranging from mild to potentially life-threatening disorders, mainly affecting the central nervous system (CNS) [52, 53] . There was a trend towards high mortality with neurological complications in our study, similarly, they were associated with significant mortality in Wang [53] observed that the occurrence of NC in adult living-donor LT did not influence the clinical outcome. The overall mortality rate until the end of follow up period was 44.9% in our study (this high rate was due to increased incidence of in-hospital mortality in our work and this was mainly in our early cases, however it improved in our late cases, furthermore, the sepsis rate that lead to in-hospital and late mortalities was high in early cases and improved after this after improving our infection control policies). However it were 24%, 39.9%, and 30% in Shin et Infection is a common cause of morbidity and mortality after liver transplantation [60, 61] . Bacterial infections, especially those involving gram-negative bacteria, represent a major complication in liver transplant recipients, the frequency ranging between 13.3% and 80% of cases, and they contribute to morbidity and mortality [15, 17, 62] . Similarly bacterial infection affected 21.6% of our patients with a trend towards significant high mortality. On the other hand it affected 51.2%, 32 [58] study and it was a cause of mortality in Du et al., 2 0 1 3 [5] and Kuramitsu et al., 2014 [44] studies. Similarly, it was the 2nd most frequent cause of in hospital mortality, and the most frequent cause of late mortality in our study.
SFSS was one of the most frequent causes of graft losses and death in Goldstein et al., 2003 [14] study. Similarly, it was the most frequent cause of in hospital mortality in our study.
Conclusions
Mortality was higher among complicated cases where vascular complications and SFSS had significant effect on it so prevention and treatment of them is required for improving outcome.
N.B: This is a retrospective cohort study limited to patients with complete data obtained from our records and patients with complete follow-up, while patients with missing data and who did not complete the follow-up were excluded.
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